Companies /Healthcare

Abbott Laboratories

NYSE: ABT Medical Devices
$111.67
▼ $2.43 (−2.13%) today
Markets open · 3:32pm ET

Q2 2025 Earnings

Reported Jul 17, 2025, 7:34am ET · SEC source
$1.26
Beat +0.80%
EPS · est. $1.25
$11.1B
Beat +1.08%
Revenue · est. $11.0B
+5.7%
Beating market
ABT vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−6%−3%0+3%Jul 17Jul 18report 7:34am ETearnings+0.6%−2.6%
−6%−3%0+3%Jul 17Jul 18earnings+0.6%−2.6%
ABT −2.6%S&P 500 +0.6%
−6%−3%0+3%Jul 17Jul 18report 7:34am ETearnings+0.6%−2.6%
−6%−3%0+3%Jul 17Jul 18earnings+0.6%−2.6%
ABT −2.6%NASDAQ +0.6%
−3%0+3%+6%Jul 16Jul 25report 7:34am ETearnings+1.8%−0.2%
−3%0+3%+6%Jul 16Jul 25earnings+1.8%−0.2%
ABT −0.2%S&P 500 +1.8%
−3%0+3%+6%Jul 16Jul 25report 7:34am ETearnings+1.3%−0.2%
−3%0+3%+6%Jul 16Jul 25earnings+1.3%−0.2%
ABT −0.2%NASDAQ +1.3%
−8.52%
Day of report
+2.62%
Next session
+4.26%
One week
+8.10%
30 days

S&P 500 over the same 30 days: +2.43%.

Did ABT Beat Earnings? Q2 2025 Results

Abbott Laboratories posted a clean beat across both top and bottom lines in the second quarter of 2025, with adjusted diluted EPS of $1.26 edging past the $1.25 consensus estimate and revenue of $11.14 billion topping expectations by 1.08% on 7.4% year-over-year growth. The primary engine behind the quarter was the Medical Devices segment, which expanded 13.4% on a reported basis, anchored by Diabetes Care, where continuous glucose monitor sales reached $1.90 billion, up 21.4% year-over-year, largely driven by FreeStyle Libre. Margin discipline was equally notable, with adjusted gross margin rising 100 basis points to 57.0% and adjusted operating margin expanding 100 basis points to 22.9%, reflecting operating leverage across the portfolio. Despite the solid print, <a href="https://247wallst.com/investing/2025/07/17/live-abbott-labs-nyse-abt-q2-earnings-updates/">shares fell sharply</a> following the release. Looking ahead, Abbott raised its full-year 2025 adjusted diluted EPS guidance to $5.10 to $5.20, implying double-digit growth at the midpoint, while projecting organic sales growth of 7.5% to 8.0% excluding COVID-19 testing.

Key Takeaways
  • Double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology within Medical Devices
  • Continuous glucose monitor sales of $1.9 billion, up 21.4% reported
  • Strong performance of FreeStyle Libre, Navitor, TriClip, and AVEIR products
  • Adult Nutrition organic growth of 6.6% led by Ensure and Glucerna
  • Established Pharmaceuticals Key Emerging Markets organic growth of 8.7% with double-digit growth in several countries across Asia, Latin America, and the Middle East
  • 100 basis point expansion in both adjusted gross margin and adjusted operating margin

“Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline. We see this momentum carrying into 2026.”

Abbott Laboratories CEO, on the earnings call

Forward Guidance & Outlook

Abbott projects full-year 2025 organic sales growth of 7.5% to 8.0% excluding COVID-19 testing-related sales, or 6.0% to 7.0% including COVID-19 testing-related sales. Full-year 2025 adjusted diluted EPS is projected at $5.10 to $5.20, reflecting double-digit growth at the midpoint. Third-quarter 2025 adjusted diluted EPS is projected at $1.28 to $1.32. Full-year adjusted operating margin is expected to be approximately 23.5% of sales.

ABT YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$4.0B$8.0B$12.0B$10.4B$11.1BRevenue$5.3B$5.9BGross Profit$1.7B$2.1BOperating Income$1.3B$1.8BNet Income
$0$4.0B$8.0B$12.0BRevenueGross ProfitOperating IncomeNet Income

ABT Revenue by Segment

Medical Devices
Diagnostics$2.2B−1.0%
Nutrition$2.2B+2.9%
Continuous Glucose Monitors$1.9B+21.4%
Diabetes Care
Established Pharmaceuticals$1.4B+6.9%
Core Laboratory Diagnostics
Adult Nutrition$1.2B+6.1%

ABT Revenue by Geography

Rest of World
United States

Figures from SEC filings and company reports. Not investment advice.